Differential effects of CD20+ B cells and PD-L1+ immune cells on pathologic complete response and outcome: comparison between inflammatory breast cancer and locally advanced breast cancer patients.
Differential effects of CD20+ B cells and PD-L1+ immune cells on pathologic complete response and outcome: comparison between inflammatory breast cancer and locally advanced breast cancer patients.
复制标题
CD20+ B细胞和PD-L1+ 免疫细胞对病理完全缓解和结果的差异影响：炎性乳腺癌和局部晚期乳腺癌患者的比较。
DOI：
10.1007/s10549-021-06391-5
复制
发表时间：
2021-12
影响因子：
3.8
通讯作者：
Fiering S
中科院分区：
文献类型：
--
作者：
Arias-Pulido H;Cimino-Mathews AM;Chaher N;Qualls CR;Joste N;Colpaert C;Marotti JD;Chamberlin MD;Foisey MG;Prossnitz ER;Emens LA;Fiering S
本研究评估了与炎症性（IBC）和局部晚期乳腺癌（LABC）患者的病理完全缓解（pCR）、乳腺癌特异性生存期（BCSS）和无病生存期（DFS）结局相关的流行病学和免疫因素。在221例IBC和162例LABC患者中，通过免疫组织化学沿着临床病理因素（作为pCR和结局的修饰因素）分析肿瘤浸润淋巴细胞（TIL）和CD 20 + B细胞（CD 20+）频率以及肿瘤（PD-L1+癌细胞）和免疫（PD-L1+ TIL）细胞上的PD-L1表达。分析包括Kaplan-Meier曲线和考克斯比例风险模型。IBC和LABC显示出相似水平的TIL、CD 20+以及组合的CD 20+和PD-L1+ TIL（CD 20 +PD-L1+ TIL），而LABC含有更多的PD-L1+ TIL和PD-L1+癌细胞。IBC和LABC患者中淋巴血管受累的缺失、高TIL、PD-L1+癌细胞以及CD 20+和PD-L1+癌细胞的组合与pCR相关。高PD-L1+ TIL仅在LABC中与pCR相关;诊断时淋巴结受累较少，CD 20+和CD 20 +PD-L1+ TIL仅在IBC中与pCR相关（P < 0.04，所有比较）。IBC和LABC患者pCR的实现与BCSS和DFS相关（P < 0.02）。在多变量分析中，pCR仍然是IBC和LABC患者DFS改善的独立预后因素，但仅是LABC的BCSS。CD 20 +PD-L1+ TIL仅在IBC中仍是DFS和BCSS改善的独立预后因素。CD 20 +PD-L1+ TIL是IBC结局改善的独立预后生物标志物，但不是LABC。通过CD 20和PD-L1状态选择IBC患者可以对患者进行分层，并可能确定可以探索活化CD 20药物和抗PD-1/PD-L1治疗的患者。
This study evaluated epidemiologic and immune factors associated with pathologic complete response (pCR), breast cancer-specific survival (BCSS) and disease-free survival (DFS) outcomes in inflammatory (IBC) and locally advanced breast cancer (LABC) patients. Tumor-infiltrating lymphocytes (TILs) and CD20+ B-cell frequencies (CD20+), and PD-L1 expression on tumor (PD-L1+carcinoma cells) and immune (PD-L1+TILs) cells were analyzed by immunohistochemistry along with clinicopathologic factors as modifiers of pCR and outcomes in 221 IBC and 162 LABC patients. Analysis included Kaplan–Meier curves and Cox proportional hazard models. IBC and LABC display similar levels of TILs, CD20+, and combined CD20+ and PD-L1+TILs (CD20+PD-L1+TILs), while LABC contained more PD-L1+TILs and PD-L1+ carcinoma cells. Absence of lymphovascular involvement, high TILs, PD-L1+ carcinoma cells, and combined CD20+ and PD-L1+ carcinoma cells correlated with pCR in IBC and LABC patients. High PD-L1+TILs correlated with pCR only in LABC; less lymph node involvement at diagnosis, CD20+ and CD20+PD-L1+TILs correlated with pCR only in IBC (P < 0.04, all comparisons). Achievement of pCR in IBC and LABC patients correlated with BCSS and DFS (P < 0.02). In multivariate analyses, pCR remained an independent prognostic factor of improved DFS in IBC and LABC patients, but of BCSS in only LABC. CD20+PD-L1+TILs remained an independent prognostic factor of improved DFS and BCSS only in IBC. CD20+PD-L1+TILs are an independent prognostic biomarker of improved outcomes in IBC, but not LABC. Selecting IBC patients by CD20 and PD-L1 status could stratify patients and potentially identify those in whom activating CD20 agents and anti-PD-1/PD-L1 therapy could be explored.
登录
查看更多内容
影响因子：
3.5
作者：
He, Jing;Huo, Lei;Gong, Yun
通讯作者：
Gong, Yun
影响因子：
3.8
作者：
Arias-Pulido H;Cimino-Mathews A;Chaher N;Qualls C;Joste N;Colpaert C;Marotti JD;Foisey M;Prossnitz ER;Emens LA;Fiering S
通讯作者：
Fiering S
影响因子：
3.1
作者：
Cristofanilli, Massimo;Gonzalez-Angulo, Ana Maria;Hortobagyi, Gabriel N
通讯作者：
Hortobagyi, Gabriel N
影响因子：
10.3
作者：
Hance, KW;Anderson, WF;Levine, PH
通讯作者：
Levine, PH
影响因子：
168.9
作者：
Gianni, Luca;Eiermann, Wolfgang;Baselga, Jose
通讯作者：
Baselga, Jose